$FOMX Foamix Pharmaceuticals Ltd. Insider Trading Week 10/2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Foamix Pharmaceuticals Ltd..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Foamix Pharmaceuticals Ltd. in week 10/2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Option Exercise | D | 4.03 | 96,365 | 388,351 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Option Exercise | D | 4.03 | 96,365 | 388,351 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Option Exercise | D | 4.06 | 100,000 | 406,000 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Option Exercise | D | 4.06 | 100,000 | 406,000 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Sell | D | 0.00 | 78,799 | 0 | 0 | 78.8 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Sell | D | 0.00 | 78,799 | 0 | 0 | 78.8 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Sell | D | 0.00 | 35,275 | 0 | 78,799 | 114.1 K to 78.8 K (-30.92 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Sell | D | 0.00 | 35,275 | 0 | 78,799 | 114.1 K to 78.8 K (-30.92 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 4.03 | 96,365 | 388,351 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 4.03 | 96,365 | 388,351 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 3.77 | 75,997 | 286,509 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 3.77 | 75,997 | 286,509 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 6.35 | 30,000 | 190,500 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 6.35 | 30,000 | 190,500 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 5.39 | 13,000 | 70,070 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 5.39 | 13,000 | 70,070 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 8.54 | 40,000 | 341,600 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 8.54 | 40,000 | 341,600 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Sell | D | 0.00 | 91,303 | 0 | 0 | 91.3 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Sell | D | 0.00 | 91,303 | 0 | 0 | 91.3 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Sell | D | 0.00 | 12,333 | 0 | 91,303 | 103.6 K to 91.3 K (-11.90 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Sell | D | 0.00 | 12,333 | 0 | 91,303 | 103.6 K to 91.3 K (-11.90 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 3.53 | 38,156 | 134,691 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 3.53 | 38,156 | 134,691 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 2.66 | 49,412 | 131,436 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 2.66 | 49,412 | 131,436 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 5.02 | 24,883 | 124,962 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 5.02 | 24,883 | 124,962 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 4.69 | 21,435 | 100,466 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 4.69 | 21,435 | 100,466 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 11.87 | 24,000 | 284,849 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 11.87 | 24,000 | 284,849 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Sell | D | 0.00 | 112,200 | 0 | 0 | 112.2 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Sell | D | 0.00 | 112,200 | 0 | 0 | 112.2 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Option Exercise | D | 10.80 | 3,000 | 32,403 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Option Exercise | D | 10.80 | 3,000 | 32,403 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Option Exercise | D | 5.88 | 8,000 | 47,032 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Option Exercise | D | 5.88 | 8,000 | 47,032 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Sell | D | 0.00 | 43,030 | 0 | 0 | 43 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Sell | D | 0.00 | 43,030 | 0 | 0 | 43 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Sell | D | 0.00 | 15,714 | 0 | 43,030 | 58.7 K to 43 K (-26.75 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Sell | D | 0.00 | 15,714 | 0 | 43,030 | 58.7 K to 43 K (-26.75 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Option Exercise | D | 5.02 | 49,766 | 249,825 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Option Exercise | D | 4.69 | 82,153 | 385,298 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Option Exercise | D | 5.88 | 27,000 | 158,760 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Sell | D | 0.00 | 59,016 | 0 | 0 | 59 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Sell | D | 0.00 | 182,500 | 0 | 59,016 | 241.5 K to 59 K (-75.56 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Sell | D | 0.00 | 52,842 | 0 | 241,516 | 294.4 K to 241.5 K (-17.95 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Option Exercise | D | 4.03 | 96,365 | 388,351 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Option Exercise | D | 3.77 | 70,297 | 265,020 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Option Exercise | D | 6.35 | 50,000 | 317,500 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Sell | D | 0.00 | 85,490 | 0 | 0 | 85.5 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Sell | D | 0.00 | 12,742 | 0 | 85,490 | 98.2 K to 85.5 K (-12.97 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 4.03 | 96,365 | 388,351 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 3.81 | 94,996 | 361,935 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 6.40 | 35,093 | 224,595 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 5.22 | 196,205 | 1,024,190 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 10.31 | 60,389 | 622,611 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 6.34 | 60,000 | 380,400 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 7.13 | 202,004 | 1,440,289 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 6.77 | 18,000 | 121,860 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 5.46 | 24,125 | 131,723 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 1.92 | 5,469 | 10,500 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Sell | D | 0.00 | 116,501 | 0 | 0 | 116.5 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Sell | D | 0.00 | 14,077 | 0 | 116,501 | 130.6 K to 116.5 K (-10.78 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Option Exercise | D | 4.03 | 240,912 | 970,875 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Option Exercise | D | 3.77 | 170,993 | 644,644 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Option Exercise | D | 5.06 | 70,187 | 355,146 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Option Exercise | D | 5.76 | 327,720 | 1,887,339 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Option Exercise | D | 10.22 | 71,369 | 729,248 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Option Exercise | D | 6.04 | 60,000 | 362,400 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Option Exercise | D | 7.14 | 236,810 | 1,690,823 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Option Exercise | D | 7.98 | 18,750 | 149,700 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Sell | D | 0.00 | 233,126 | 0 | 0 | 233.1 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Sell | D | 0.00 | 90,902 | 0 | 233,126 | 324 K to 233.1 K (-28.05 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Bruno Anthony D | Director | Sell | D | 0.00 | 12,360 | 0 | 0 | 12.4 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Bruno Anthony D | Director | Sell | D | 0.00 | 62,647 | 0 | 12,360 | 75 K to 12.4 K (-83.52 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Bright Rex | Director | Option Exercise | D | 3.53 | 38,156 | 134,691 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Bright Rex | Director | Option Exercise | D | 2.66 | 49,412 | 131,436 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Bright Rex | Director | Option Exercise | D | 5.06 | 24,947 | 126,232 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Bright Rex | Director | Option Exercise | D | 4.76 | 21,562 | 102,635 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Bright Rex | Director | Option Exercise | D | 5.88 | 27,000 | 158,760 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | BARBARI SHARON SURREY | Director | Option Exercise | D | 2.66 | 49,412 | 131,436 | 0 |